Processa Pharmaceuticals held annual shareholder meeting, quorum met by proxy or in person

• Processa Pharmaceuticals held its 2026 annual shareholder meeting on July 30, 2026.
• Shareholders backed an amended 2019 omnibus incentive plan, authorizing an additional 200,000 shares for issuance under the plan.
• Shareholders ratified Cherry Bekaert as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
• Shareholders approved the slate of six directors to serve until the next annual meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Processa Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-036032), on August 04, 2026, and is solely responsible for the information contained therein.